MOR208C310

Name No. For Patients with Purpose
MOR208C310 20-35

Newly-diagnosed diffuse large B-cell lymphoma (DLBCL).

This Study is comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).


Paradigme (LYMRIT-37-01)

Name No. For Patients with Purpose
Paradigme (LYMRIT-37-01) 18-15

Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment.

To investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects.